NASDAQ:XOMA - XOMA Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$23.02 -0.09 (-0.39 %)
(As of 07/16/2018 04:00 PM ET)
Previous Close$23.11
Today's Range$22.72 - $23.22
52-Week Range$6.86 - $37.25
Volume46,600 shs
Average Volume151,987 shs
Market Capitalization$193.64 million
P/E Ratio14.72
Dividend YieldN/A
XOMA logoXOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody designed to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; and other preclinical product candidates, such as interleukin 2, a therapy for metastatic melanoma and renal cell carcinoma, as well as anti-parathyroid receptor to address unmet medical needs. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration and licensing agreements with Novartis AG; Takeda Pharmaceutical Company Limited; and Pfizer Inc. XOMA Corporation was founded in 1981 and is headquartered in Emeryville, California.

Receive XOMA News and Ratings via Email

Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity Ratio2.59
Current Ratio7.26
Quick Ratio7.26


Trailing P/E Ratio14.72
Forward P/E Ratio-29.14
P/E GrowthN/A

Sales & Book Value

Annual Sales$52.69 million
Price / Sales3.66
Cash Flow$2.1178 per share
Price / Cash10.87
Book Value$0.71 per share
Price / Book32.42


EPS (Most Recent Fiscal Year)$0.98
Net Income$14.59 million
Net Margins40.44%
Return on Equity-670.15%
Return on Assets56.39%


Outstanding Shares8,380,000
Market Cap$193.64

The Truth About Cryptocurrencies

XOMA (NASDAQ:XOMA) Frequently Asked Questions

What is XOMA's stock symbol?

XOMA trades on the NASDAQ under the ticker symbol "XOMA."

How were XOMA's earnings last quarter?

XOMA Corp (NASDAQ:XOMA) posted its earnings results on Wednesday, May, 9th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.52) by $0.07. The biotechnology company earned $0.46 million during the quarter, compared to analyst estimates of $3.69 million. XOMA had a negative return on equity of 670.15% and a net margin of 40.44%. View XOMA's Earnings History.

When is XOMA's next earnings date?

XOMA is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for XOMA.

What price target have analysts set for XOMA?

3 Wall Street analysts have issued 12 month price objectives for XOMA's shares. Their forecasts range from $33.00 to $49.00. On average, they anticipate XOMA's share price to reach $41.00 in the next year. This suggests a possible upside of 78.1% from the stock's current price. View Analyst Ratings for XOMA.

What is the consensus analysts' recommendation for XOMA?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Are investors shorting XOMA?

XOMA saw a increase in short interest during the month of June. As of June 29th, there was short interest totalling 905,211 shares, an increase of 73.6% from the June 15th total of 521,409 shares. Based on an average trading volume of 214,835 shares, the short-interest ratio is currently 4.2 days. Currently, 11.7% of the shares of the stock are sold short. View XOMA's Current Options Chain.

Who are some of XOMA's key competitors?

Who are XOMA's key executives?

XOMA's management team includes the folowing people:
  • Mr. James R. Neal, CEO & Director (Age 62)
  • Mr. Thomas M. Burns, Sr. VP of Fin. & CFO (Age 44)
  • Mr. Danny J. Hart Jr., VP & Gen. Counsel (Age 42)
  • Dr. Deepshikha Datta, Chief Bus. Officer
  • Dr. Kirk W. Johnson Ph.D., VP of Devel. (Age 58)

Has XOMA been receiving favorable news coverage?

Media coverage about XOMA stock has trended somewhat positive this week, according to Accern. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. XOMA earned a media sentiment score of 0.16 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 45.95 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

How do I buy shares of XOMA?

Shares of XOMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is XOMA's stock price today?

One share of XOMA stock can currently be purchased for approximately $23.02.

How big of a company is XOMA?

XOMA has a market capitalization of $193.64 million and generates $52.69 million in revenue each year. The biotechnology company earns $14.59 million in net income (profit) each year or $0.98 on an earnings per share basis. XOMA employs 12 workers across the globe.

How can I contact XOMA?

XOMA's mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-204-7239 or via email at [email protected]

MarketBeat Community Rating for XOMA (NASDAQ XOMA)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  308 (Vote Outperform)
Underperform Votes:  268 (Vote Underperform)
Total Votes:  576
MarketBeat's community ratings are surveys of what our community members think about XOMA and other stocks. Vote "Outperform" if you believe XOMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XOMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.